What JRF Global does

JRF Global (legal name Jai Research Foundation) is a privately-held, India-headquartered non-clinical GLP contract research organization founded in 1977 and operating from a 158,000+ square foot purpose-built facility in Vapi, Gujarat, supported by wholly-owned subsidiaries in the United Kingdom (since 1998), the United States (since 2008), and a regional presence in Japan. The company delivers Good Laboratory Practice (GLP) compliant safety testing services that generate the regulatory submission data required by FDA, EMA, OECD, ICH, JMAFF, and OCSPP, including mammalian toxicology, genotoxicity, safety pharmacology (including jacketed dog telemetry), inhalation toxicology, ecotoxicology, environmental fate and metabolism, product/residue chemistry, DART, DMPK/bioanalysis, and an in vitro cosmetic testing battery built on 3Rs principles. Its infrastructure includes GLP-compliant animal facilities with AAALAC accreditation (since 2009), a 320 sq. metre pathology laboratory with four veterinary pathologists, an inhalation toxicology facility with nose-only and whole-body exposure systems, and a dedicated IT/biostatistics department supporting electronic data capture (Xybion Pristima/Savante LIMS).

The company monetizes through project-based B2B contracts with quotes determined per study, covering approximately 600 customers across pharmaceutical, agrochemical/crop protection, specialty chemicals/REACH, biocidal products, cosmetics, and veterinary/biopesticides segments. Notable customers include India's top-ranked pharmaceutical company, multiple Japanese and Chinese multinationals, and a US-based MNC that rated JRF as the world's second-best mutagenicity facility. Distribution is enterprise field-sales driven, with multi-year contracts, dedicated business development coverage across time zones, and presence at SOT, SETAC, ACT, NAICC, and SQA Texas conferences. Recent product extensions include the Biocelerate partnership model targeting resource-constrained biotechs with IND-enabling ADMET packages.

Strategic positioning is anchored in regulatory accreditations (OECD GLP via NGCMA, AAALAC, OLAW F22-00563, CPCSEA, FDA FEI 3014694901, BARC nuclear regulatory approval), a global QA unit operating at a 1:6 auditor-to-study-director ratio, and recent entry into New Approach Methodologies (NAMs) ecosystems through the FNIH Validation & Qualification Network and the 3Rs Collaborative in 2025. AI/ML is applied narrowly in computational toxicology (3D-QSAR modeling) rather than across the service portfolio, and the company is privately held with no disclosed funding, M&A, or ownership structure beyond founder/management involvement.

Name

JRF Global

Legal name

Jai Research Foundation

Website

https://jrfglobal.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

251–500 employees

Short description

JRF Global is a non-clinical GLP contract research organization based in Gujarat, India, providing regulatory toxicology, ecotoxicology, chemistry, and environmental fate services to pharmaceutical, agrochemical, specialty chemical, biocide, cosmetic, and veterinary product companies across India, the US, UK, and Japan.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industries

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• GLP contract research
• Preclinical safety testing
• Regulatory toxicology services
• Ecotoxicology testing
• Environmental fate studies

Headquarters

HQ city

Gujrat

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Project-based contract research services for regulatory submissions. Services include Toxicology, Ecotoxicology, Chemistry, Environmental Fate and Metabolism studies. Pricing based on study complexity, regulatory requirements, and turnaround time. Sponsors receive comprehensive study reports for regulatory submissions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

JRF Global is a non-clinical GLP Contract Research Organization delivering integrated regulatory research services including Toxicology, Ecotoxicology, Chemistry, Environmental Fate, and Metabolism studies. Services span Pharma/Bio Pharma, Crop Care/Agrochemicals, REACH/Specialty Chemicals, Biocides, Cosmetics, and Microbial Pesticides verticals, with sub-services covering genotoxicity, safety pharmacology, DMPK/metabolism, DART studies, bioanalytics, and impurity qualification. The company executes study design, conduct, and regulatory report generation on a project-based contract basis for sponsors seeking global regulatory submission support.

Product overview

JRF Global (Jai Research Foundation) is a non-clinical GLP contract research organization offering integrated regulatory research services across six core service lines: Pharma/Bio Pharma, Crop Care, REACH/Specialty Chemicals, Biocides, Cosmetics, and Microbial Pesticides. The portfolio includes dedicated sub-services such as Biocelerate (IND-enabling partnership model), genotoxicity, safety pharmacology, DMPK/metabolism, in vitro ADME, DART studies, and bioanalytical services. JRF serves pharmaceutical, agrochemical, specialty chemical, biocidal, cosmetic, and veterinary product industries across global locations (India, USA, Japan), with over 600 client companies served. The company operates from 158,000+ sq. ft. of purpose-built GLP-compliant laboratories with AAALAC-accredited animal facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Biocelerate: Partnership model that helps sponsors cost-effectively deepen and broaden their discovery pipelines, offering services to resource-constrained biotech companies to derisk pipeline assets by front-loading screens for therapeutic class liabilities.

Products and services

• Pharma / Bio Pharma Services Comprehensive non-clinical GLP research services for pharmaceutical and biopharmaceutical products including IND/NDA/ANDA-enabling studies, mammalian toxicology, genotoxicity, safety pharmacology, DMPK/metabolism studies, DART, impurity profiling, bioanalytical services, and environmental risk assessment for global regulatory submissions.
• Crop Care Services Safety studies for global regulatory compliance of crop protection chemicals including 5 Batch analysis, physico-chemical studies, toxicology, ecotoxicology, environmental fate and metabolism, residue studies, and efficacy field trials for herbicides, fungicides, insecticides, biocides, and related products.
• REACH / Specialty Chemicals Services Regulatory compliance services for specialty chemicals and industrial biotech under REACH requirements including toxicology, reprotoxicology, inhalation toxicology, ecotoxicology, genetic toxicology, product chemistry, and regulatory affairs consultancy for inorganic, organic, petrochemical, polymer, oleochemical, fragrance, and flavor chemicals.
• Biocides Services Comprehensive testing services for biocidal products under EU BPR regulations including chemistry, toxicology, ecotoxicology, and environmental fate studies for global registration of disinfectants, preservatives, anti-fouling agents, and pest control products.
• Cosmetics Services Alternative testing methods for cosmetics including in vitro dermal absorption, skin corrosion, eye irritation, skin sensitization, phototoxicity, BCOP assay, genotoxicity, and method development following 3Rs principles for new ingredients and finished products.
• Microbial Pesticides Services Testing services for microbial pest control agents including product chemistry, toxicology, and ecotoxicology studies following OPPTS guidelines under GLP for bacteria, algae, fungi, viruses, and protozoa-based biopesticides.
• Biocelerate Partnership model that helps resource-constrained biotech companies and virtual drug discovery organizations derisk pipeline assets through ADMET screening and IND-enabling GLP studies with rapid turnaround and customized pricing.
• IND Evaluation Services IND-enabling safety evaluation including mammalian toxicology, genetic toxicology, DMPK, safety pharmacology, immunotoxicity, neurotoxicity, bioanalysis, and regulatory submission guidance for FDA, EMA, and other bodies.
• NDA / ANDA Evaluation Services Comprehensive NDA/ANDA enabling safety evaluation services including ADMET testing for regulatory submissions.
• Safety Pharmacology GLP-compliant cardiovascular studies using conscious dog telemetry with jacketed technology, plus CNS, respiratory, and gastrointestinal assessments following ICH S7A/S7B guidelines.
• Chronic Toxicity Studies Mammalian toxicology assessments in rodents and non-rodents including single dose, MTD, 4-52 week repeated exposure, carcinogenicity, and combined studies with various routes of administration.
• Subchronic Inhalation Studies Inhalation toxicology facility for rodents with nose-only exposure systems, cascade impactor analysis, gravimetric estimation, and comprehensive histopathological evaluation of respiratory organs.
• Genotoxicity Services In vitro and in vivo genetic toxicology assays including Ames test, chromosome aberration, HPRT mutation, micronucleus tests, and dermal absorption studies following OECD, EPA, ICH, and JMAFF guidelines.
• Endocrine Disruptor Screening (EDSP) Two-tiered endocrine disruptor screening program including in vitro (ER binding, aromatase, AR binding, ER transcriptional activation, steroidogenesis) and in vivo assays (uterotrophic, Hershberger, pubertal development) following OPPTS guidelines.
• DMPK and Metabolism Studies In vivo radiolabeled ADME studies and pharmacokinetics/bioavailability/bioequivalence studies using LC-MS/MS, WinNonlin software for PK/TK analysis, and comprehensive metabolite profiling.
• In vitro ADME Early-stage ADME screening assays including PAMPA, microsomal stability, plasma protein binding, CYP inhibition, reaction phenotyping, and blood-brain barrier binding.
• DART (Developmental and Reproductive Toxicity) Comprehensive DART studies following ICH S5(R3) including fertility/embryonic development (Segment I), embryo-fetal development (Segment II), pre/postnatal studies (Segment III), and juvenile toxicity studies.
• Impurity / Metabolite Qualification Impurity profiling and qualification studies including isolation, purification, characterization using spectrometry, and toxicological safety evaluation for pharmaceutical impurities.
• Bio-analytical Services Bioanalysis using LC-MS/MS and HPLC with method development and validation in biological matrices, toxicokinetic analysis, and ELISA services.
• In vitro Genotox (Cosmetics) In vitro genotoxicity testing for cosmetics including Ames test, chromosome aberration, HPRT assay, and micronucleus test using OECD-compliant methods.
• In vitro Skin Sensitization Three-tiered in vitro skin sensitization testing following OECD 442C (DPRA), 442D (KeratinoSens), 442E (hCLAT), and U-SENS assays based on adverse outcome pathway principles.
• In vitro Dermal Absorption In vitro dermal absorption studies using automated flow-through diffusion system with human and rat skin following OECD guidelines for agrochemical and cosmetic risk evaluation.

Quantifiable outcome

• 100% regulatory acceptance rate for study reports submitted to FDA and EU agencies
• +4 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Foundation for the National Institutes of Health (FNIH)flagshipStrategic or Co-development Partner · 5 August 2025JRF Global is collaborating with FNIH as part of the Validation & Qualification Network (VQN), a public-private partnership designed to accelerate adoption of New Approach Methodologies (NAMs). The VQN unites over forty public, private, and nonprofit partners to advance innovations such as organs-on-chip, AI-driven models, and advanced cell systems. JRF is participating in the VQN design phase to help bring transformative technologies into mainstream practice.
• 3Rs CollaborativecoreStrategic or Co-development Partner · 22 July 2025JRF Global has joined the 3Rs Collaborative, a non-profit organization committed to advancing science through Replacement, Reduction, and Refinement of animal use in research. The partnership supports JRF's commitment to ethical research practices and expands the reach of 3Rs-aligned technologies including AI-based monitoring tools, in vitro models, and refined animal-handling procedures.
• Xybion CorporationcoreTechnology or Integration · 12 March 2018JRF signed Pristima and Savante Software Licensing Agreement with Xybion Corporation in March 2018. The agreement provides JRF with advanced laboratory information management and electronic data capture systems for GLP-compliant study management.
• JRF America, USAcoreOthers · 1 January 2008US operations established in 2008 to support North American pharmaceutical, agrochemical, and chemical companies requiring GLP-compliant non-clinical research services.
• JRF International Ltd., UKcoreOthers · 1 January 1998International collaboration established in 1998 as part of JRF's global expansion strategy to serve clients worldwide with GLP-compliant research services.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Largest global preclinical CRO offering a full range of GLP toxicology, safety pharmacology, and research models. Directly comparable in non-clinical GLP safety testing services, but operates at significantly larger scale with integrated discovery and clinical offerings.
• LabCorp (Covance): Global CRO providing preclinical toxicology and safety assessment services through its Covance segment. Comparable in regulatory GLP testing scope, with broader integrated clinical diagnostics and central lab services.
• WuXi AppTec: Chinese-headquartered CRO with extensive preclinical toxicology, DMPK, and safety assessment services. Competes directly with JRF for global pharma preclinical outsourcing with comparable cost-arbitrage positioning.
• Eurofins Scientific: Global testing services group with substantial life-sciences and agrochemical testing capabilities. Overlaps with JRF's regulatory toxicology, ecotoxicology, and chemistry testing services at a much larger scale.
• SGS (Life Sciences): Global testing, inspection, and certification company with a Life Sciences division covering preclinical and agrochemical GLP testing. Comparable in regulatory safety testing and chemistry services across multiple verticals.
• Intertek: Global quality assurance provider with agricultural and life sciences testing services including GLP toxicology and ecotoxicology. Comparable in regulatory compliance testing for agrochemicals and chemicals.

Direct peers

• Sai Life Sciences: India-based CRO offering preclinical GLP toxicology, DMPK, and drug discovery services to global pharma. Closely comparable to JRF in scale, India-based cost advantage, and integrated preclinical service portfolio.
• Syngene International: India-based contract research and manufacturing organization offering preclinical and clinical services. Comparable India-based CRO serving pharma and agrochemical clients with GLP testing and broader discovery capabilities.
• Pharmaron: Global CRO with strong preclinical toxicology and DMPK services, including operations in China and the UK. Directly comparable in GLP safety assessment and IND-enabling service offerings.
• Aragen Life Sciences (formerly GVK Biosciences): India-headquartered CRO offering preclinical toxicology, DMPK, and integrated discovery-to-development services. Comparable India-based CRO with overlapping preclinical safety assessment capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jrfglobal
• Facebookfacebook.com/JRFGlobal
• LinkedInlinkedin.com/company/jrf-global

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JRF Global